Aiolos approach is similar to that of Upstream Bio  which launched in June 2022 and raised new funds earlier this year. Upstream is also targeting TSLP and announced positive Phase 1 results Tuesday. Upstream said the study shows high potency for its drug UPB101  and the company will explore dosing every 12 weeks and every 24 weeks in a Phase 2 trial for severe asthma